Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,046.8
-16.4 (-0.54%)

 

  • STI Straits Times Index
    3,046.8
    -16.4 (-0.54%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,526.9
    -3.5 (-0.23%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,099.1
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,595.0
    -19.0 (-0.53%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,647.8
    -192.0 (-0.64%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,089.4
    28.6 (0.47%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 461.5M
  • Value: 372.5M
  • Rise: 100
  • Fall: 115
  • Unch: 540

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.082-0.003
Asian Micro0.008+0.001
Aspen0.156+0.030
Hatten Land0.068-0.001
YZJ Shipbldg SGD1.390-0.040
China Star Food0.029+0.005
VCPlus0.029+0.001
CapLand IntCom T2.080+0.030
Biolidics0.240+0.005
China Env Res0.014+0.003

World Indices

World Indices
Name Last Change
Nasdaq 14,746.4 +32.5
HSI 24,099.1
HSCEI 8,638.5
Jakarta 6,086.4 +25.6
Nikkei 225 29,662.2 -177.6
SSE Comp 3,589.5 -24.5
Shanghai A 3,762.0 -25.7
Shanghai B 274.3 +1.1
KOSPI 3,130.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IGBB IGB BERHAD
Quotes 15 Minutes Delayed. Updated at 22 Sep 2021 09:13
Last (MYR): 1.870 Change: - High: 1.870 Remarks: s
Remarks legend:
RemarksDescriptionRemarksDescription
IOrder entry forbiddenAOrder entry authorized
GFrozenSSuspended
RReservedsShort selling available
[x]Exclude dividend[c] Cum dividend
Change (%): - Low: 1.870
Open 1.870 Yesterday's Close 1.870
Buy Price 1.890 Sell Price 1.910
Buy Volume ('00) 250 Sell Volume ('00) 50
Cumulative Volume ('00) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (MYR) a 0.01033 Trailing EPS (MYR) e -0.00747 NAV (MYR) b 3.9594
PE a 181.026 Trailing PE f - Price / NAV b 0.4723
Dividend (MYR) d - Cash In Hand (MYR) g 0.8512 Issued & Paid-up Shares c 895,878,396
Dividend Yield (%) d - Price / Cash In Hand g 2.197 Treasury Shares h 9,472,000
Beta - 75 Daysi 0.511 R-Squared - 75 Days(%)i 0.78 Market Cap (M) 1,675.293
Beta - 500 Daysi 0.426 R-Squared - 500 Days (%)i 4.18 Enterprise Value (M) 5,135.369
Piotroski F Score 4 Exchange Code 5606 Par Value ( MYR ) 1.00000
52 Weeks Volatility (%) 125.97 6-Month VWAP 0.855 Free Float (%) 40.0
Sector & Industry Health Technology - Pharmaceuticals: Major
Index Components Bursa Malaysia Properties Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 21 Sep 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 21 Sep 2021.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IGBB Bursa 1,675.293 181.026 - 0.4723 -
Industry PROPERTY Bursa 512.931 155.864 41.973 0.4743 1.463
Pharmaceuticals: Major Bursa 709.963 - - 0.6540 0.671
Index Bursa Malaysia Properties Index Bursa 611.801 143.757 38.856 0.4403 1.579
Local Peer BSTEAD Bursa 1,155.383 - - 0.3710 -
Local Peer PHARMA Bursa 1,074.166 39.085 33.619 3.0004 2.680
Local Peer KOTRA Bursa 402.491 16.502 16.502 1.9498 -
Local Peer NOVA Bursa 273.260 21.011 18.080 3.0518 1.663
Local Peer BIOHLDG Bursa 266.963 - - 1.4151 -
Local Peer SUNZEN Bursa 129.031 - - 1.3628 -
Global Peer JOHNSON & JOHNSON NYSE 433,121.934 29.436 24.378 6.2248 2.419
Global Peer PFIZER INC NYSE 246,245.825 25.608 18.615 3.5157 3.459
Global Peer ELI LILLY AND COMPANY NYSE 220,176.249 35.548 36.269 34.1656 1.286
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 202,178.581 24.898 22.479 3.7411 2.321
Global Peer ABBVIE INC NYSE 189,353.337 41.561 28.738 15.0650 4.512
Global Peer MERCK & CO INC NYSE 182,182.699 25.779 32.702 5.4719 3.444
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,200.114 57.322 48.581 11.6867 1.963
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 180,393.431 27.995 25.340 17.2541 1.322
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 134,059.896 - - 3.6421 3.080
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 121,848.565 8.680 17.595 1.6248 2.773
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), REPLIGEN CORP (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), CUREVAC NV (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), SINOPHARM (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ALLAKOS INC (NASDAQ), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), JUNSHI BIO (HKEx), CMS (HKEx), HYGEIA HEALTH (HKEx), AKESO-B (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), INNOCARE-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CARSGEN-B (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), SIMCERE PHARMA (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), ERASCA INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), EVEREST MED-B (HKEx), TRAD CHI MED (HKEx), ADC THERAPEUTICS SA (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), CSTONE PHARMA-B (HKEx), QUANTERIX CORPORATION (NASDAQ), HENLIUS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), OCUMENSION-B (HKEx), ZYMEWORKS INC (NYSE), HEPALINK (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), GENERATION BIO CO (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), KRONOS BIO INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ICOSAVAX INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), IMMUNOTECH-B (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), TONGRENTANGCM (HKEx), REPARE THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), Kimia Farma Tbk. (IDX), SCICLONE PHARMA (HKEx), GH RESEARCH PLC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ANTENGENE-B (HKEx), KINNATE BIOPHARMA INC (NASDAQ), CKLIFE SCIENCES (HKEx), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SHINEWAY PHARM (HKEx), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), PHARVARIS NV (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), BEYONDSPRING INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), TALARIS THERAPEUTICS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), CHINOOK THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), AC IMMUNE SA (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), WEREWOLF THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), 89BIO INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), RACE ONCOLOGY LTD (ASX), ESSA PHARMA INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), NEXIMMUNE INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM-B (HKEx), PYC THERAPEUTICS LIMITED (ASX), OYSTER POINT PHARMA INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), ANGION BIOMEDICA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), DAWNRAYS PHARMA (HKEx), DURECT CORP (NASDAQ), INOZYME PHARMA INC (NASDAQ), XOMA CORP (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), ANNOVIS BIO INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), MUSTANG BIO INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), IMMUNIC INC (NASDAQ), FUSEN PHARM (HKEx), GAMIDA CELL LTD (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ALZAMEND NEURO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), IP (SET), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), CH BIOTECH SER (HKEx), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), GENPREX INC (NASDAQ), ZHONGZHIPHARM (HKEx), IX Biopharma (SGX), LANTERN PHARMA INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), ETON PHARMACEUTICALS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), EYENOVIA INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), IMARA INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), SANAI HEALTH GP (HKEx), ELEDON PHARMACEUTICALS INC (NASDAQ), CRESO PHARMA LTD (ASX), GALECTO INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), OCUPHIRE PHARMA INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), RENOVORX INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), INVION LTD (ASX), MANNATECH INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), MODERN CHI MED (HKEx), WAI YUEN TONG (HKEx), EXOPHARM LTD (ASX), NEP INTERLONG (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), SEQLL INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PHARMAXIS (ASX), DERMATA THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), CNS PHARMACEUTICALS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), ASSERTIO HOLDINGS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), EXTRAWELL PHAR (HKEx), TELIGENT INC NEW (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), JCT (SET), PALLA PHARMA LTD (ASX), PAINREFORM LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), ACRUX (ASX), AVENUE THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PETROS PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.050
-2.60 %
10 Days 0.043-0.030
+0.68 %
20 Days 0.043-0.040
+0.16 %
Medium Term Return 3 Months 0.043-0.230
-8.90 %
6 Months 0.043+1.316
+245.31 %
1 Year 0.086+1.321
+256.28 %
Long Term Return 2 Years 0.222+1.278
+253.38 %
3 Years 0.433+1.337
+332.08 %
5 Years 0.493+1.304
+317.49 %
Annualised Return Annualised --
+33.09 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.526 - 2.220 Change From 1 Year Low +1.344 % Change From 1 Year Low (%) +255.45
Change From 1 Year High -0.350 % Change From 1 Year High (%) -15.77
2 Years Range 0.497 - 2.220 Change From 2 Years Low +1.373 % Change From 2 Years Low (%) +276.56
Change From 2 Years High -0.350 % Change From 2 Years High (%) -15.77
5 Years Range 0.465 - 2.220 Change From 5 Years Low +1.405 % Change From 5 Years Low (%) +302.24
Change From 5 Years High -0.350 % Change From 5 Years High (%) -15.77
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Goldis Berhad Formerly known as Gold Is Berhad. The Group's principal activities are the manufacturing of pharmaceutical products, paper-related products and provision of information technology and communication. Other activities include provision of healthcare management services, broadband web based solutions, property holding, sale of baby products and provision of engineering services for pure water and waste water treatment plants and related services. The Group is also involved in the development and management of fitness centre, trading of sports equipment and sports wear and sale of electronic products and intelligent facilities management system. The Group also undertakes investment holding. The Group operates in Malaysia, People's Republic of China, Singapore and Hong Kong.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(2.80 MB)
Annual Report 2018 Dec 2018 Part 1(2.67 MB)
Annual Report 2017 Dec 2017 Part 1(0.27 MB)
Part 2(1.83 MB)
Part 3(0.53 MB)
Annual Report 2016 Dec 2016 Part 1(1.50 MB)
Annual Report 2015 Dec 2015 Part 1(2.78 MB)
Annual Report 2014 Dec 2014 Part 1(2.89 MB)
Annual Report 2013 Dec 2013 Part 1(1.93 MB)
Annual Report 2013 Jan 2013 Part 1(2.31 MB)
Annual Report 2012 Jan 2012 Part 1(3.09 MB)
Annual Report 2011 Jan 2011 Part 1(2.50 MB)
Part 2(2.23 MB)
Annual Report 2010 Jan 2010 Part 1(2.52 MB)
Part 2(1.84 MB)
Part 3(0.04 MB)
Annual Report 2009 Jan 2009 Part 1(0.87 MB)
Annual Report 2008 Jan 2008 Part 1(0.79 MB)
Annual Report 2007 Jan 2007 Part 1(0.67 MB)
Annual Report 2006 Jan 2006 Part 1(1.63 MB)
Part 2(0.68 MB)
Part 3(0.24 MB)
Annual Report 2005 Jan 2005 Part 1(0.69 MB)
Annual Report 2004 Jan 2004 Part 1(0.40 MB)
Annual Report 2003 Jan 2003 Part 1(0.94 MB)
Annual Report 2002 Jan 2002 Part 1(0.26 MB)
Annual Report 2001 Jan 2001 Part 1(0.74 MB)
Annual Report 2000 Jan 2000 Part 1(0.32 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
21 Sep 2021 1.900 1.900 1.870 1.870 235,000 1.8927
20 Sep 2021 1.920 1.920 1.890 1.900 351,000 1.8988
17 Sep 2021 1.920 1.920 1.920 1.920 14,400 1.9200
15 Sep 2021 1.940 1.940 1.920 1.920 192,800 1.9278
14 Sep 2021 1.920 1.930 1.920 1.920 5,500 1.9236
13 Sep 2021 1.900 1.900 1.900 1.900 14,000 1.9000
10 Sep 2021 1.900 1.910 1.900 1.900 32,500 1.9022
09 Sep 2021 1.910 1.910 1.900 1.900 14,500 1.9057
08 Sep 2021 1.900 1.910 1.900 1.900 54,100 1.9000
07 Sep 2021 1.930 1.930 1.900 1.900 39,000 1.9103
06 Sep 2021 1.860 1.920 1.850 1.900 293,300 1.8644
03 Sep 2021 1.900 1.910 1.860 1.860 641,600 1.8854
02 Sep 2021 1.950 1.950 1.890 1.890 936,200 1.9024
01 Sep 2021 1.940 1.940 1.940 1.940 - -
30 Aug 2021 1.960 1.980 1.940 1.940 31,000 1.9645
27 Aug 2021 1.960 1.960 1.960 1.960 - -
26 Aug 2021 1.970 1.970 1.950 1.960 19,600 1.9597
25 Aug 2021 1.940 1.940 1.940 1.940 21,100 1.9400
24 Aug 2021 1.910 1.910 1.910 1.910 - -
23 Aug 2021 1.910 1.910 1.910 1.910 - -
20 Aug 2021 1.920 1.920 1.910 1.910 49,000 1.9169
19 Aug 2021 1.930 1.930 1.920 1.920 5,000 1.9240
Summary
Current 2 Weeks
(07 Sep 2021 to 21 Sep 2021)
1.930 1.940 1.870 1.870 952,800 -
Previous 2 Weeks
(23 Aug 2021 to 06 Sep 2021)
1.910 1.940 1.870 1.900 1,942,800 -
4 Weeks from
(23 Jul 2021 to 20 Aug 2021)
1.970 1.970 1.870 1.910 2,222,800 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.